Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · IEX Real-Time Price · USD
1.030
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
1.070
+0.040 (3.88%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Company Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG.
The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
Country | Canada |
Founded | 1998 |
IPO Date | Nov 8, 1999 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 29 |
CEO | Dr. Matthew C. Coffey M.B.A., Ph.D. |
Contact Details
Address: 804, 322 - 11 Avenue Sw Calgary, A0 T2R 0C5 Alberta, Canada | |
Phone | 4036707380 |
Website | oncolyticsbiotech.com |
Stock Details
Ticker Symbol | ONCY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001129928 |
CUSIP Number | 682310875 |
ISIN Number | CA6823108759 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Matthew C. Coffey M.B.A., Ph.D. | President, Chief Executive Officer and Director |
Kirk J. Look C.A., CA | Chief Financial Officer |
Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development |
Amy Goodowitz Levin | Vice President of Clinical Operations |
Jon Patton | Director of Investor Relations and Communication |
John Mark Lievonen BBA, C.M., FCA, LLD, MBA | Consultant |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 27, 2024 | 6-K | Report of foreign issuer |
Jun 24, 2024 | 6-K | Report of foreign issuer |
Jun 20, 2024 | 6-K | Report of foreign issuer |
Jun 4, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
May 24, 2024 | 6-K | Report of foreign issuer |
May 16, 2024 | 6-K | Report of foreign issuer |
May 15, 2024 | 6-K | Report of foreign issuer |
May 9, 2024 | 6-K | Report of foreign issuer |
May 9, 2024 | 6-K | Report of foreign issuer |
May 9, 2024 | 6-K | Report of foreign issuer |